Maladie du spectre des anticorps anti-MOG [Anti-MOG associated disease]

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 24/10/2025.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_F1DE110FEDE8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Maladie du spectre des anticorps anti-MOG [Anti-MOG associated disease]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Lerusse J., Uginet M., Théaudin M., Bernard-Valnet R., Pot C., Lalive P.H.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
24/04/2024
Peer-reviewed
Oui
Volume
20
Numéro
871
Pages
828-832
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD) is an autoimmune disease responsible for demyelination of the central nervous system that can occur in adults or children. Overlapping phenotypes between MOGAD, multiple sclerosis (MS) and neuromyelitis optica spectrum disease (NMOSD) have been described. The diagnostic criteria for MOGAD were proposed by a panel of international experts and published in 2023. Defining clinical, biological and imaging characteristics specific to this entity helps to improve diagnostic specificity. In this article, we present the clinical characteristics suggestive of MOGAD and discuss the importance of the antibody detection method and therapeutic management.
Mots-clé
Humans, Myelin-Oligodendrocyte Glycoprotein/immunology, Neuromyelitis Optica/diagnosis, Neuromyelitis Optica/immunology, Autoantibodies/immunology, Autoantibodies/blood, Multiple Sclerosis/diagnosis, Multiple Sclerosis/immunology, Adult, Child, Autoimmune Diseases/diagnosis, Autoimmune Diseases/immunology
Pubmed
Création de la notice
03/05/2024 13:24
Dernière modification de la notice
04/05/2024 6:20
Données d'usage